Moffitt logo

Articles related to Triple Negative Breast Cancer

Herpes Virus

TVEC for the Treatment of Early Stage Triple Negative Breast Cancer

TVEC is designed to preferentially lyse tumor cells over normal tissue to release tumor associated antigens, produces GM-CSF to activate dendritic cells, and stimulates T cells to infiltrate the tumor (TILs). TILs in breast cancer are associated with better response to neoadjuvant chemotherapy (NAC). This phase 2 trial hypothesized that intratumoral TVEC may enhance response to NAC. Read More

Breast Cells

Combining Immunotherapy in Triple Negative Breast Cancer Treatment

Responses have been seen in some patients with triple-negative breast cancer (TNBC), signaling a potential role for immunotherapy in this tumor type. Read More


Ask the Experts: Your Questions About the Breast Cancer Vaccine Answered

Dr. Brian Czerniecki, chair of the breast cancer program at Moffitt Cancer Center, connected with our Facebook friends in the Ask The Experts series to answer your questions about the breast cancer vaccine. Read More

Cancer Survivor Gives Back to Organization that ‘Saved Her Life’

Moffitt experts to discuss breast cancer prevention and treatment options at Sarasota luncheon Read More

Susan G. Komen Awards Moffitt researcher $450,000 Grant to Study New Treatments for Triple Negative Breast Cancer

Will study how cancer associated fibroblasts decrease the effectiveness of therapies Read More


Pamela's Story

My dogs helped get me through the toughest fight of my life. In early 2014, when I was diagnosed with triple negative breast cancer, I was 38. Read More